Clinical Trial Update: Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination [Phase 3]

View source ↗

Summary

Phase 3 trial updating immunogenicity, reactogenicity, and safety of GlaxoSmithKline's MenACWY-TT meningococcal vaccine when administered six years after primar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• MenACWY-TT Vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2019-01-25